Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention.
about
Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentratesTreatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXTreatment options for bleeding episodes in patients undergoing immune tolerance therapy.The pharmacokinetics of clotting factor therapy.Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.Hemophilia: treatment options in the twenty-first century.Home management of haemophilia.Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patientsHaemophilia therapies.Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.Back to the future: a recent history of haemophilia treatment.Pain and pain management in haemophilia.Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.Home treatment of haemophilia patients with inhibitors.Pharmacotherapy of haemophilia A.Exploring the biological basis of haemophilic joint disease: experimental studies.Recombinant activated factor VII in clinical practice: a 2014 update.Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.Optimising musculoskeletal care for patients with haemophilia.Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitorsA prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey.Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.Optimizing joint function: new knowledge and novel tools and treatments.
P2860
Q27026389-CECEF3D8-06D0-4108-BF81-38600C2D358BQ33608230-82E99BF3-CE7B-4385-9F6A-AEDB47BF093CQ33794095-7E8CE68C-3163-4CBF-9134-ED9EC25D4470Q35163599-F4FAC3B8-ED4F-42DA-B31A-8AF9543C6F2DQ35163644-BAA05AA2-D3FF-45C7-8714-90BE38B3C360Q35181577-4505D832-E58D-4715-B7D8-32C4480C44E6Q35666730-776A31A8-12AB-43BA-9B63-419FB8B06457Q35771690-7E646AC1-561E-48BC-BCD7-290906803B42Q36480548-32562F0A-5678-4B1D-9252-8A98C91E5A73Q36536184-AD9DAA81-5EFB-4A8D-BA31-EFC1284230E0Q36570888-0972380E-1781-4F00-A7E0-70F593B42532Q36745575-465DF990-A680-427A-B66A-378C4A2D1C41Q36810282-5B2886F2-F281-4ACB-BE85-2B03F3549DF2Q36828144-719F7C01-A899-40C3-B59F-0277ADC4DC51Q36945941-4B208F0F-5E55-469C-8E4C-428BEA0212A1Q37176481-CD12A5A3-1165-41FC-8098-3CD1C65FE100Q37381096-DA26A825-A3BA-4143-B89C-84A8086A1771Q37609087-A2225A23-19A8-4112-9238-036BB8B6D61CQ37778291-59BDE366-C8D2-498D-8EF7-1CC07FCF5E14Q37808746-5A6C457B-921F-4916-B601-676B0D95018AQ37891089-546C4BC8-FDC7-44BC-9470-EA9A7294E544Q37951686-B66723C2-A9CF-4925-AA9F-C6EBD403AE27Q38228494-A8AF40DA-406D-4194-83E7-7F25581F654AQ38546790-67BD47A0-DBD8-44FE-B412-9128221DCC46Q38672487-325EF13C-D407-4F50-877F-E8F71014F8E5Q39173721-5AA48ACE-BD16-40C5-862E-73FA3F2BBFA4Q39392420-3DB4207D-1804-4F87-B26D-A6A2B38D8F6CQ40539842-B39306A8-288F-4038-A3D8-A63AB3663CD9Q45855313-70097915-F2CC-4464-98A9-84E6ADFC782DQ45863879-FC836B23-393F-4846-9175-02ABA334DAA3Q45864880-279ADCB7-4760-4827-8BB4-C149DBEAC788Q45867004-3A1E7431-9708-4A63-9D8A-34FF5955FAD3Q45867946-B7513747-2433-41F7-94DB-B1631EB97928Q45871901-24967774-545B-4289-8D37-E3A7497A5D7FQ45872630-FD2A8409-81A4-4E0C-A94F-7B0551A3EC95Q45873703-015D1BF2-F41C-43FC-BD39-FC63634B3855Q45875224-8D7CC4C6-DF37-49F1-A3A0-65F7F0F6B96CQ45877257-57D8D550-491B-4D51-9515-CA2179479916Q45879815-53400F52-07BE-47B2-B937-C137B613962BQ45880179-F90295F5-BAD5-4466-AC13-8F33EBEBD46C
P2860
Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Home treatment with recombinan ...... antages of early intervention.
@en
Home treatment with recombinan ...... antages of early intervention.
@nl
type
label
Home treatment with recombinan ...... antages of early intervention.
@en
Home treatment with recombinan ...... antages of early intervention.
@nl
prefLabel
Home treatment with recombinan ...... antages of early intervention.
@en
Home treatment with recombinan ...... antages of early intervention.
@nl
P2093
P2860
P1476
Home treatment with recombinan ...... antages of early intervention.
@en
P2093
Gringeri A
Mannucci PM
Santagostino E
P2860
P356
10.1046/J.1365-2141.1999.01128.X
P407
P577
1999-01-01T00:00:00Z